Beta
ManageSearchChatDiscover
223253

Anti-Glutamic Acid Decarboxylase 65 as a Predictor of Progressive Insulin Deficiency in Type 2 Diabetes

Article

Last updated: 22 Jan 2023

OverviewSimilar Items

Subjects

-

Tags

Clinical Research (Medical)

Abstract

Background: For type 2 diabetes, there are few usual highly specific indicators, though the presence of risk factors such as obesity indicates the likelihood of developing type 2 diabetes. Aim:To assess the anti-glutamic acid decarboxylase 65 (anti-GAD65) level in type 2 Egyptian Diabetic patients and if it could be used as a marker for progression to insulin deficiency and treatment with insulin. Patients and Methods: a cross-sectional study was conducted on 100 patients with type 2 diabetes mellitus (T2DM) who were divided into group1 as 50 patients on oral antidiabetic drugs (OADs) for more than 5 years and another 50 patients as group 2 on insulin after being previously on OADs. Patients with type 1 diabetes, T2DM associated with any auto-immune disease, T2DM with chronic kidney disease (CKD), or chronic liver disease (CLD) were excluded. Full history taking, clinical examination, and liver and kidney functions were performed in addition to FBS, HbA1c, C- peptide, and anti-glutamic acid decarboxylase 65 (anti- GAD65) antibody. Results: statistically significant positive correlation between Anti-GAD 65 levels and age (r=0.262, P-value=0.008) and negative correlation between Anti-GAD 65 levels and fasting C-peptide (r=-0.27, P-value=0.006) were found. Conclusion: Anti-glutamic acid decarboxylase antibody 65 is more positive in the OAD group than in the insulin group but it is not p-value significant. Anti-glutamic acid decarboxylase antibodies are positively correlated with age also,it is negatively correlated with fasting C-peptide. So, it can be used as a marker for pancreatic reserve and progressive Insulin Deficiency in type 2 Egyptian patients.
 

DOI

10.21608/scumj.2022.223253

Keywords

Anti-glutamic acid decarboxylase 65, Type 2 Diabetes, Insulin, oral antidiabetic drugs

Authors

First Name

Mohammed

Last Name

Hamed

MiddleName

-

Affiliation

Department of Internal Medicine and Endocrinology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.

Email

mohamedsaad@med.asu.edu.eg

City

-

Orcid

-

First Name

Ahmed

Last Name

Bahaaeldin

MiddleName

M.

Affiliation

Department of Internal Medicine and Endocrinology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.

Email

-

City

-

Orcid

-

First Name

Bassem

Last Name

Mostafa

MiddleName

M.

Affiliation

Department of Internal Medicine and Endocrinology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.

Email

basemmurad44@med.asu.edu.eg

City

-

Orcid

-

Volume

25

Article Issue

2

Related Issue

31648

Issue Date

2022-07-01

Receive Date

2022-03-07

Publish Date

2022-07-01

Page Start

12

Page End

18

Print ISSN

1110-6999

Online ISSN

2090-2581

Article File

SCUMJ_Volume 25_Issue 2_Pages 12-18.pdf

PDF . 250.8kB

Link

https://scumj.journals.ekb.eg/article_223253.html

Detail API

https://scumj.journals.ekb.eg/service?article_code=223253

Order

3

Type

Original Article

Type Code

938

Publication Type

Journal

Publication Title

Suez Canal University Medical Journal

Publication Link

https://scumj.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023